Episode
Case Study: FDA’s New Expectation for Use-Related Risk in Medical Device Submissions
- Podcast
- Let's Talk Risk! Podcast
- Published
- Jun 19, 2026
- Duration seconds
- 2486
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/let-s-talk-risk-podcast-6693844/episodes/case-study-fda-s-new-expectation-for-use-related-risk-in-medical-device-submissions/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/let-s-talk-risk-podcast-6693844/case-study-fda-s-new-expectation-for-use-related-risk-in-medical-device-submissions.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
You cannot reverse engineer your human factors regulatory strategy at the 11th hour. FDA’s new human factors guidance is not just about what goes into a marketing submission. It changes the way teams need to think about use-related risk, critical tasks, labeling, training, post-market evidence, and design change control across the product lifecycle. In this audio case study, we walk through why Category 3 human factors validation may become the default concern when critical tasks are introduced or impacted and why Decision Point D is not a shortcut, but an evidence-based exception that depends on history of use, user interface complexity, and the adequacy of existing risk controls. Key highlights covered in the audio: * Why human factors can no longer be treated as a late-stage submission activity * How use-related risk analysis drives the identification of critical tasks * Why Category 3 validation may be triggered by more than obvious design changes * How Decision Point D may reduce submission burden — but only with strong evidence * Why post-market surveillance data now has direct pre-market strategic value Keywords: FDA human factors guidance, medical device marketing submissions, use-related risk analysis, critical tasks, Category 3 human factors validation, Decision Point D, eSTAR, QMSR, medical device usability, post-market surveillance, design validation, medical device labeling. 🎧Click Play above to listen to a brief audio summary about this case and lessons QA/RA and Clinical professionals can apply in practice using the newly released FDA Guidance. Thanks for reading Let's Talk Risk! . If you liked this post, share with others. Note: The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for thi…